Protein-based therapeutic killing for cancer therapies
The treatment of some high-incidence human diseases is based on therapeutic cell killing.
In cancer this is mainly achieved by chemical drugs that are systemically administered to …
In cancer this is mainly achieved by chemical drugs that are systemically administered to …
[HTML][HTML] Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review …
S Pusceddu, M Ghidini, M Torchio, F Corti… - Cancers, 2019 - mdpi.com
Gemcitabine and nab-paclitaxel (GEM-NAB) and the combination of 5-fluorouracil,
oxaliplatin, and irinotecan (FOLFIRINOX) are valid first-line options for advanced or …
oxaliplatin, and irinotecan (FOLFIRINOX) are valid first-line options for advanced or …
Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma
A Klein-Brill, S Amar-Farkash, G Lawrence… - JAMA network …, 2022 - jamanetwork.com
Importance FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan
hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first …
hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first …
[HTML][HTML] Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy
CK Hirt, TH Booij, L Grob, P Simmler, NC Toussaint… - Cell genomics, 2022 - cell.com
Pancreatic cancer (PDAC) is a highly aggressive malignancy for which the identification of
novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank …
novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank …
[HTML][HTML] Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies
E van Veldhuisen, C van den Oord, LJ Brada… - Cancers, 2019 - mdpi.com
Locally advanced pancreatic cancer (LAPC) has several definitions but essentially is a
nonmetastasized pancreatic cancer, in which upfront resection is considered not beneficial …
nonmetastasized pancreatic cancer, in which upfront resection is considered not beneficial …
Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery
Y Miyasaka, T Ohtsuka, R Kimura, R Matsuda… - Annals of surgical …, 2019 - Springer
Background Accumulation of evidence suggests that neoadjuvant chemotherapy improves
the outcomes of borderline resectable pancreatic cancer (BRPC). Gemcitabine plus nab …
the outcomes of borderline resectable pancreatic cancer (BRPC). Gemcitabine plus nab …
[HTML][HTML] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line
treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently …
treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently …
Ruxolitinib+ capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III …
H Hurwitz, E Van Cutsem, J Bendell, M Hidalgo… - Investigational new …, 2018 - Springer
Summary Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus
capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of …
capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of …
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
EG Chiorean, WY Cheung… - … in medical oncology, 2019 - journals.sagepub.com
Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G)
with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced …
with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced …
[HTML][HTML] The role of FOLFIRINOX in metastatic pancreatic cancer: A meta-analysis
B Zhang, F Zhou, J Hong, DM Ng, T Yang… - World Journal of …, 2021 - Springer
Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …